Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2015 | main topic | Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015

Biological agents in psoriatic arthritis

Zeitschrift:
Wiener Medizinische Wochenschrift > Ausgabe 1-2/2015
Autoren:
MD Roland Kocijan, MD Christian Muschitz, MD Jürgen Rech

Summary

Anti-tumor necrosis factors (TNFs) are effective drugs for the treatment of psoriatic arthritis (PsA) regarding reduction of pain and inflammation, enthesitis, dactylitis, as well as psoriatic skin and nail disease. Moreover, radiographic progression in PsA is decelerated. The efficacy of anti-TNFs seems to be independent of synthetic disease-modifying anti-rheumatic drugs, suggesting only a minor role of combination therapy in PsA. Anti-TNFs are generally well tolerated in patients with PsA. Adverse events are similar to those reported in patients with rheumatoid arthritis. Ustekinumab, a recently approved IL-12/IL-23-antibody is another promising biological agent in the treatment of PsA.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015 Zur Ausgabe

themenschwerpunkt

Biologika bei SLE